PET imaging: implications for the future of therapy monitoring with PET/CT in oncology
作者： Giampaolo Tomasi , Lula Rosso
DOI: 10.1016/J.COPH.2012.07.016
关键词: Tumour volume 、 Response to treatment 、 Pet imaging 、 Oncology 、 Molecular imaging 、 Tracer uptake 、 Therapy monitoring 、 Medicine 、 Neoplasms diagnosis 、 Internal medicine 、 Nuclear medicine 、 PET-CT
摘要: Among the methods based on molecular imaging, measure of tracer uptake variation between a baseline and follow-up scan with SUV [(18)F]FDG-PET/CT is very powerful tool for assessing response to treatment in oncology. However, development new targeted therapeutics tissue pharmacokinetic evaluation existing ones are increasingly requiring therapy monitoring alternative tracers indicators. In parallel, potential predictive prognostic value other image-derived parameters, such as tumour volume textural features, relating tumoral heterogeneity, has recently emerged from several works.
elsevier.com
sci-hub.se 参考文章(62)
Stephan Luderschmidt, Anca-Ligia Grosu, Maria-Jose Martinez, Ingo Wolf, Ambros J Beer, Markus Niemeyer, Roland Haubner, Hans Jürgen Wester, Markus Schwaiger, Michael Goebel, Wolfgang A Weber, PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. The Journal of Nuclear Medicine. ,vol. 47, pp. 763- 769 ,(2006)
Wolfgang A Weber, Use of PET for Monitoring Cancer Therapy and for Predicting Outcome The Journal of Nuclear Medicine. ,vol. 46, pp. 983- 995 ,(2005)
Balaji Ganeshan, Sandra Abaleke, Rupert C.D. Young, Christopher R. Chatwin, Kenneth A. Miles, Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage Cancer Imaging. ,vol. 10, pp. 137- 143 ,(2010) , 10.1102/1470-7330.2010.0021
M. P.S. Dunphy, J. S. Lewis, Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET The Journal of Nuclear Medicine. ,vol. 50, ,(2009) , 10.2967/JNUMED.108.057281
Giampaolo Tomasi, Federico Turkheimer, Eric Aboagye, Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Molecular Imaging and Biology. ,vol. 14, pp. 131- 146 ,(2012) , 10.1007/S11307-011-0514-2
Adriaan A. Lammertsma, Corneline J. Hoekstra, Giuseppe Giaccone, Otto S. Hoekstra, How should we analyse FDG PET studies for monitoring tumour response European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 33, pp. 16- 21 ,(2006) , 10.1007/S00259-006-0131-5
Daniela Thorwarth, Susanne-Martina Eschmann, Felix Holzner, Frank Paulsen, Markus Alber, Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiotherapy and Oncology. ,vol. 80, pp. 151- 156 ,(2006) , 10.1016/J.RADONC.2006.07.033
Lula Rosso, Cathryn S. Brock, James M. Gallo, Azeem Saleem, Patricia M. Price, Federico E. Turkheimer, Eric O. Aboagye, A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Research. ,vol. 69, pp. 120- 127 ,(2009) , 10.1158/0008-5472.CAN-08-2356
Dan Ribom, Marjoleine Schoenmaekers, Henry Engler, Anja Smits, Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. Journal of Neuro-oncology. ,vol. 71, pp. 325- 332 ,(2005) , 10.1007/S11060-004-2031-5
Bernd Kasper, Gerlinde Egerer, Martina Gronkowski, Sabine Haufe, Thomas Lehnert, Michael Eisenhut, Gunhild Mechtersheimer, Anthony D. Ho, Uwe Haberkorn, Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leukemia & Lymphoma. ,vol. 48, pp. 746- 753 ,(2007) , 10.1080/10428190601113568